Review of thalidomide in the treatment of newly diagnosed multiple myeloma

Therapeutics and Clinical Risk Management

Volumn 3, Issue 4, 2007, Pages 543-552

  Cavallo, Federica ^a   Boccadoro, Mario ^a   Palumbo, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Front line therapy; Multiple myeloma; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; STEROID; THALIDOMIDE; VINCRISTINE; WARFARIN; ZOLEDRONIC ACID;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CELL CYCLE ARREST; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; IMMUNOMODULATION; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MEDLINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; REVIEW; RISK REDUCTION; SALVAGE THERAPY; SEDATION; SIDE EFFECT; STEM CELL MOBILIZATION; THROMBOSIS PREVENTION; TREATMENT DURATION;

EID: 34848879192     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Abdelkefi A, Torjman L, Ben Romdhane N, et al. 2005. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant, 36(3):193-8.
2. Alexanian R, Haut A, Khan AU, et al. 1969. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA, 208(9):1680-5.
3. Alexanian R, Weber D, Giralt S, et al. 2002. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol, 13(7):1116-9.
4. Alexanian R, Weber D, Anagnostopoulos A, et al. 2003. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol, 40(4 Suppl 4):3-7. Review.
5. Anagnostopoulos A, Weber D, Rankin K, et al. 2003. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol, 121(5):768-71.
6. Attal M, Harousseau JL, Stoppa AM, et al. 1996. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med, 335:91-97.
7. Attal M, Harousseau JL, Leyvraz S, et al. 2006. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 108 (10):3289-3294.
8. Barlogie B, Tricot G, Rasmussen E, et al. 2005. Total Therapy 3 (TT3) Incorporating Velcade® (V) Intro Upfront Management of Multiple Myeloma (MM): Comparison with TT2 + Thalidomide (T). Blood, 106:abstract 1154.
9. Barlogie B, Tricot G, Anaissie E, et al. 2006. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med, 354(10):1021-30.
10. Berenson JR, Yang HH, Sadler K, et al. 2006. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol, 24(6):937-44.
11. Brinker BT, Waller EK, Leong T, et al. 2006. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer, 106(10):2171-2180.
12. Cavo M, Zamagni E, Tosi P, et al. 2004. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica, 89(7):826-31.
13. Cavo M, Zamagni E, Tosi P, et al. 2005. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood, 106(1):35-9.
14. Child JA, Morgan GJ, Davies FE, et al. 2003. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med, 348(19):1875-83
15. Clagett GP, Reisch JS, 1988. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg, 208:227-40
16. Cohen HJ, Crawford J, Rao MK, et al. 1998. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med, 104(5):439-44
17. Davies FE, Raje N, Hideshima T, et al. 2001. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98(1):210-6.
18. Dimopoulos MA, Moulopoulos A, Smith T, et al. 1993. Risk of disease progression in asymptomatic multiple myeloma. Am J Med, 94(1):57-61.
19. Dimopoulos MA, Moulopoulos LA, Maniatis A, et al. 2000. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood, 96(6):2037-44. Review.
20. Dimopoulos MA, Zervas K, Kouvatseas G, et al. 2001. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol, 12(7):991-5.
21. Dimopoulos MA, Hamilos G, Zomas A, et al. 2004. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J, 5(2):112-7.
22. Dimopoulos MA, Anagnostopoulos A, Terpos E, et al. 2006. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica, 91(2):252-4.
23. Dingli D, Rajkumar SV, Nowakowski GS, et al. 2005. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica, 90(12):1650-4.
24. Facon T, Mary JY, Hulin C, et al. 2005. Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma. Blood, 106:abstract 780.
25. Feyler S, Rawstron A, Jackson G, et al. 2005. Thalidomide Maintenance Following High Dose Therapy in Multiple Myeloma: a UK Myeloma Forum Phase 2 Study. Blood, 106:abstract 641.
26. Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, et al. 2002. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can bean option for relapsed/refractory multiple myeloma. Hematol J, 3(1):43-8.
27. Ghobrial IM, Dispenzieri A, Bundy KL, et al. 2003. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant, 32(6):587-92.
28. Goldschmidt H, Sonneveld P, Breitkreuz I, et al. 2005. HOVON 50/ GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years. Blood, 106:abstract 424.
29. Gonzales-Porras JR, Garcia-Sanz R, Polo-Zarzuela M, et al. 2003. ThalCyDex in relapsed/refractory multiple myeloma. Haematology Journal, 4:S234.
30. Gupta D, Treon SP, Shima Y, et al. 2001. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 15(12):1950-61.
31. Harousseau JL. 2002. High-dose therapy in multiple myeloma. Ann Oncol, 13 Suppl 4:49-54.
32. Hassoun H, Reich L, Klimek VM, et al. 2006. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol, Jan;132(2):155-61.
33. Hideshima T, Anderson KC. 2002. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer, 2(12):927-37. Review.
34. Hideshima T, Chauhan D, Shima Y, et al. 2000. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96(9):2943-50.
35. Hjorth M, Hellquist L, Holmberg E, et al. 1993. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomized study. Myeloma Group of Western Sweden. Eur J Haematol, 50(2):95-102.
36. Hussein MA, Elson P, Tso EA, et al. 2003. Decadron and Thalidomide (DVd-T) for relapsed/refractory multiple myeloma. Haematology Journal, 4:S235-S236.
37. Hussein MA, McCoy J, Jakubowiak A, et al. 2005. SWOG 0204: Phase 2 Trial of Thalidomide (T) + Dexamethasone (D) Induction Followed by Tandem Autotransplant (TAT) and Prednisone (P) + T Maintenance for Multiple Myeloma(MM). Blood, 106:abstract 1169.
38. Kyle RA, Greipp PR. 1980. Smoldering multiple myeloma. N Engl J Med, 302(24):1347-9.
39. Kropff MH, Lang N, Bisping G, et al. 2003. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol, 122(4):607-16.
40. Kumar S, Gertz MA, Dispenzieri A, et al. 2003. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc, 78(1):34-9.
41. Lee CK, Barlogie B, Munshi N, et al. 2003. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol, 21(14):2732-9.
42. Lentzsch S, LeBlanc R, Podar K, et al. 2003. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia, 17(1):41-4.
43. Ludwig H, Drach J, Tothova E, et al. 2005. Thalidomide dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis. Blood, 106:abstract 782.
44. Mateos MV, Hernández JM, Hernández MT, et al. 2006. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 108 (7):2165-2172.
45. Moehler TM, Neben K, Benner A, et al. 2001. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood, 98(13):3846-8.
46. Offidani M, Corvatta L, Piersantelli MN, et al. 2006. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood, 108(7):2159-64
47. Palumbo A, Giaccone L, Bertola A, et al. 2001. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica, 86(4):399-403.
48. Palumbo A, Bertola A, Musto P, et al. 2005. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer, 104(7):1428-33.
49. Palumbo A, Ambrosini MT, Ptegno P, et al. 2005. Velcade™ plus melphalan, prednisone, and thalidomide (V-MPT) for advanced multiple myeloma. Blood, 106:abstract 2553.
50. Palumbo A, Bringhen S, Caravita T, et al. 2006. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 367(9513):825-31.
51. Rajkumar SV, Dispenzieri A, Fonseca R, et al. 2001. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia, 15(8):1274-6.
52. Rajkumar SV, Hayman S, Gertz MA, et al. 2002. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol, 20(21):4319-23.
53. Rajkumar SV, Gertz MA, Lacy MQ, et al. 2003. Thalidomide as initial therapy for early-stage myeloma. Leukemia, 17(4):775-9.
54. Rajkumar SV, Blood E, Vesole D, et al. 2006. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol, 24(3):431-6.
55. Sahebi F, Spielberger R, Kogut NM, et al. 2006. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant, 37(9):825-9.
56. San Miguel JF, Blade Creixenti J, Garcia-Sans R. 1999. Treatment of multiple myeloma. Haematologica, 84(1):36-58
57. Schutt P, Ebeling P, Buttkereit U, et al. 2005. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol, 74(1):40-6.
58. Singhal S, Mehta J, Desikan R, et al. 1999. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341(21):1565-71.
59. Terpos T, Anagnostopoutos A, Kastritis E, et al. 2005. The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) is an effective treatment for relapsed/refractory myeloma: Results of a Phase II Clinical Trial. Blood, 106:abstract 363.
60. Wang M, Weber DM, Delasalle K, et al. 2005. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol, 79(3):194-7.
61. Wang M, Delasalle K, Giralt S, et al. 2005. Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Thalidomide-Dexamethasone Followed by Early Intensive Therapy. Blood, 106:abstract 784.
62. Weber DM, Gavino M, Delasalle K, et al. 1999. Thalidomide alone or with dexamethasone for multiple myeloma. Blood, 94:suppl 1, 604a.
63. Weber D, Rankin K, Gavino M, et al. 2003. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol, 21(1):16-9.
64. Williams CD, Byrne JL, Sidra G, et al. 2004. Combination Chemotherapy with Cyclophosphamide, Thalidomide and Dexamethasone Achieves a High Response Rate in Patients with Newly Diagnosed, VAD-Refractory and Relapsed Myeloma. Blood, 104:abstract 1499.
65. Zangari M, Siegel E, Barlogie B, et al. 2002. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood, 100(4):1168-71.
66. Zangari M, Barlogie B, Anaissie E, et al. 2004. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol, 126(5):715-21.
67. Zangari M, Barlogie B, Burns MJ, et al. 2005. Velcade (V)-Thalidomide (T)-Dexamethasone (D) for Advanced and Refractory Multiple Myeloma (MM): Long-Term Follow-Up of Phase I-II Trial UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T. Blood, 106:abstract 2552.
68. Zervas K, Dimopoulos MA, Hatzicharissi E, et al. 2004. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol, 15(1):134-8.